(Press-News.org) A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to treat overactive bladder symptoms, reduces hot flashes compared to the placebo in men receiving hormone therapy for prostate cancer. This primary analysis of Alliance A222001 is published in the Journal of Clinical Oncology.
“Oxybutynin demonstrated clear and clinically meaningful improvements in both hot flash frequency and quality of life for men undergoing hormone therapy for prostate cancer,” said Bradley J. Stish, MD, the study’s lead investigator and a radiation oncologist at the Mayo Clinic. “These results provide strong support for its use as an effective management option for this challenging and often overlooked side effect of prostate cancer treatment.”
Androgen-deprivation therapy (ADT) is an effective treatment against prostate cancer as it lowers male hormones like testosterone needed to fuel cancer cells. However, ADT causes hot flashes in up to 80 percent of the men who take it, leading to fatigue, sleep disturbances and reduced quality of life, often leading patients to discontinue ADT due to the side effects.
The Phase II randomized, double‑blind, placebo‑controlled trial evaluated whether two doses of oxybutynin (2.5 mg twice daily and 5 mg twice daily) could improve hot flash symptoms compared with placebo over six weeks. The study enrolled 88 men from 15 academic and community cancer centers; 81 participants were eligible for final analysis. The average age of the participants was 68.5.
In this trial, both doses of oxybutynin substantially improved hot flash symptoms compared to the placebo over the six‑week treatment period. Men receiving placebo experienced an average reduction of 2.15 hot flashes per day and a 4.85‑point drop in daily hot flash severity scores, whereas those taking 2.5 mg of oxybutynin twice daily reported reductions of 4.77 hot flashes per day and a 9.94‑point decrease in severity, and those receiving 5 mg twice daily experienced the largest improvements, with 6.89 fewer hot flashes per day and a 13.95‑point reduction in severity.
Improvements occurred quickly, often during the first week of treatment, and were sustained throughout the study. The proportion of patients achieving at least a 50 percent reduction in hot flash scores was also markedly higher with oxybutynin: 57 percent in the 2.5 mg group and 79 percent in the 5 mg group, compared with 32 percent taking placebo. Treatment was well tolerated overall. Dry mouth was the most common side effect reported.
“These results are incredibly encouraging,” added Dr. Stish. “Men with hot flashes from hormone therapy now have another therapeutic option available to help reduce their symptom burden. Future research will look to further our understanding of hot flash therapy options in this patient population.”
In addition to the Mayo Clinic in Rochester, MN, investigators on the study included scientists from the Alliance Protocol Operations in Chicago, IL; Alliance Statistics and Data Management Center at the Mayo Clinic in Scottsdale, AZ; Aspirus Regional Cancer Center in Wausau, WI; Ellis Fischel Cancer Center in Columbia, MO; Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Gibbs Cancer Center in Spartanburg, SC; Mayo Clinic Division of Nursing in Jacksonville, FL; Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine in New York, NY; SCOR-Messino Cancer Centers in Ashville, NC; Sidney Kimmel Cancer Center in Baltimore, MD; The Ohio State University in Columbus, OH; and Yale University School of Medicine, New Haven, CT.
The study was supported by the National Cancer Institute of the National Institutes of Health under the Award Number UG1CA189823 (Alliance for Clinical Trials in Oncology NCORP Grant); UG1CA239762, UG1CA189858, UG1CA239758, and UG1CA239769
###
References: Alliance A222001 - A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy
Journal of Clinical Oncology: Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer
The Alliance for Clinical Trials in Oncology is a national leader in advancing cancer research, uniting more than 25,000 cancer specialists at 115 main institutions and 1,400 affiliates across the U.S. and Canada. As part of the National Clinical Trials Network and a leading research base for the NCI Community Oncology Research Program, the Alliance conducts pioneering, practice-changing clinical trials that improve outcomes and reshape standards of care. Its work has led to multiple FDA approvals, influenced national guidelines, and produced hundreds of high-impact publications. More than 40,000 participants have taken part in Alliance studies, and its growing biospecimen repository now includes more than 1.5 million samples, collected over the past 30 years. Learn more at www.AllianceforClinicalTrialsinOncology.org.
END
By changing the physical structure of gold at the nanoscale, researchers can drastically change how the material interacts with light – and, as a result, its electronic and optical properties. This is shown by a study from Umeå University published in Nature Communications.
Gold plays a crucial role in modern advanced technology thanks to its unique properties. New research now demonstrates that changing the material's physical structure – its morphology – can fundamentally enhance both its electronic behaviour and its ability to interact with light.
“This might make it possible to improve the efficiency of chemical reactions such as those used in hydrogen ...
The first study to test a digital tool designed to help people with Long COVID manage their energy levels has been developed by a team of researchers.
The paper published in Nature Communications is entitled “A Digital Platform with Activity Tracking for Energy Management Support in Long COVID: A Randomised Controlled Trial”.
In this study, funded by the National Institute for Health and Care Research (NIHR), people with Long COVID tried out a new app called “Pace Me” to help manage their energy levels. The tool combines a wearable activity tracker (Fitbit watch) with an app that sends helpful messages throughout the day, reminding users ...
Generative AI models have been used to create enormous libraries of theoretical materials that could help solve all kinds of problems. Now, scientists just have to figure out how to make them.
In many cases, materials synthes is not as simple as following a recipe in the kitchen. Factors like the temperature and length of processing can yield huge changes in a material’s properties that make or break its performance. That has limited researchers’ ability to test millions of promising model-generated materials.
Now, MIT researchers have created an AI model that guides scientists ...
A sediment core from the Pacific sector of the Southern Ocean has provided a research team led by geochemist Dr Torben Struve from the University of Oldenburg, Germany, with evidence of an unexpected climate feedback in Antarctica. As the team reports in the latest issue of Nature Geoscience, there was a close correlation between changes in the West Antarctic Ice Sheet (WAIS) and marine algae growth over previous glacial cycles – but the correlation was not as expected. Based on the results, the team concludes ...
Scientists have created a complete map showing how hundreds of possible mutations in a key cancer gene influence tumour growth.
The study focused on CTNNB1, a gene that produces the protein β-catenin, which helps regulate tissue growth and repair. When β-catenin is disrupted, cells can begin uncontrolled growth – a hallmark of cancer.
By systematically testing all possible mutations in a priority area of the gene in mouse cells, the map helps explain why certain mutations appear in specific cancers and could guide the development of new treatments, experts say.
Many cancers carry mutations ...
A new study in Nature Geoscience reveals that changes in the West Antarctic Ice Sheet (WAIS) closely tracked marine algae growth in the Southern Ocean over previous glacial cycles, but not in the way scientists expected.
The key factor is iron-rich sediments transported by icebergs from West Antarctica.
Iron acts like fertilizer for algae. But when analyzing a sediment core taken from the Pacific sector of the Southern Ocean in 2001, more than three miles below the water’s surface, researchers were surprised to find that a high iron supply did not accelerate marine algae growth.
“Normally, an increased supply of iron in the Southern Ocean would stimulate algae ...
People born more recently are being diagnosed with psychotic disorders (e.g., schizophrenia) more often and at younger ages than people born earlier, suggests a large study of more than 12 million people in Ontario, published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.250926.
“Individuals with psychotic disorders face substantial morbidity and risk of premature death, and often require substantial health services and social support,” writes Dr. Daniel Myran, Gordon F. Cheesbrough ...
The fossils, representing at least five individuals, were first uncovered by Fidel Torcida Fernández-Baldor of the Dinosaur Museum of Salas de los Infantes. “From the beginning, we knew these bones were exceptional because of their minute size. It is equally impressive how the study of this animal overturns global ideas on ornithopod dinosaur evolution,” he notes.
The genus name Foskeia is derived from the ancient Greek. The prefix fos means ‘light’, given the very lightweight and small body size of grown individuals (Dieudonné et al. 2023). The combination of letters ...
UNDER EMBARGO UNTIL 01:00AM (GMT) MONDAY 2ND FEB 2026
New research from the University of St Andrews has discovered a crucial piece in the puzzle of how all animals with a spine - including all mammals, fish, reptiles and amphibians - evolved.
In a paper published today (2nd February) in BMC Biology, researchers found an intriguing pattern of gene evolution which appears to be significant for the evolutionary origin and diversification of vertebrates.
All animals have major ...
Aortic Hemiarch Reconstruction Safely Matches Complex Aortic Arch Reconstruction for Acute Dissection in Older Adults
NEW ORLEANS—February 1, 2026—Ascending aortic hemiarch reconstruction offers the same long-term benefits to patients over age 65 with acute type A aortic dissection (ATAAD) as more complex extended arch reconstruction procedures, according to a study presented today at the 2026 Society of Thoracic Surgeons Annual Meeting.
The finding came from a risk-adjusted analysis of 3,562 patients examining long-term survival and surgical reintervention for aortic disease following initial operation for ATAAD. Patient data came from the STS ...
